Relationship Between Great Toe Strength And Symptoms of Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Eligibility Criteria for Chemotherapy-Induced Peripheral Neuropathy (CIPN) group: Who May Qualify: - At least 18 years of old with the ability to independently raise and low (extend or flex) the great toe - Able to consent and complete questionnaires in English independently and have normal to corrected vision (self-reported) - Within 3 - 6 months of starting chemotherapy and a confirmed diagnosis of CIPN using the current clinical reference standard of Nerve conduction study. Who Should NOT Join This Trial: - Comorbidities including but not limited to diabetes, arthritis, hypertension, thyroid disease, and heart disease, . that have been reported to be associated with the incidence of peripheral neuropathy and/or progression of CIPN. - Toe deformities or impairments not caused by CIPN (including but not limited to hallux valgus/varus, hallux limitus, hallux rigidus, hammer toe deformity, claw toe, bunions, webbed toes) - Self-reported impairment or impact on the strength of the foot, ankle, and/or great toe due to past medical or surgical history. Eligibility Criteria for Healthy Control group: The participants recruited for this group will be age- and sex- matched to the CIPN group - Who May Qualify: - At least 18 years of old with the ability to independently raise and low (extend or flex) the great toe - Able to consent and complete questionnaires in English independently and have normal to corrected vision (self-reported) - No known health conditions that have been reported to be associated with different impairements in mobility, balance, and muscle strength (particularly in the lower extremity) Always talk to your doctor about whether this trial is right for you.